Kendra D. Carter

Array ( [id] => 9575537 [patent_doc_number] => 08765949 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-01 [patent_title] => 'CCR2 receptor antagonists and uses thereof' [patent_app_type] => utility [patent_app_number] => 12/969745 [patent_app_country] => US [patent_app_date] => 2010-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48449 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12969745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8516774 [patent_doc_number] => 20120316183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-13 [patent_title] => 'NOVEL SOLVATES OF METHYLCARBAMATE' [patent_app_type] => utility [patent_app_number] => 13/515682 [patent_app_country] => US [patent_app_date] => 2010-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 8156 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13515682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9026595 [patent_doc_number] => 08536178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-09-17 [patent_title] => 'Pharmaceutical composition for preventing or treating diseases associated with beta-amyloid accumulation containing morpholin or piperazine based compounds having SO3H or COOH as active ingredient' [patent_app_type] => utility [patent_app_number] => 12/960977 [patent_app_country] => US [patent_app_date] => 2010-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 5734 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12960977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9869342 [patent_doc_number] => 08957114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-17 [patent_title] => 'Formulations, salts and polymorphs of transnorsertraline and uses thereof' [patent_app_type] => utility [patent_app_number] => 13/513170 [patent_app_country] => US [patent_app_date] => 2010-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 10 [patent_no_of_words] => 36137 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13513170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8956045 [patent_doc_number] => 08501819 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-06 [patent_title] => 'Stabilized compositions of volatile alkylating agents and methods of using thereof' [patent_app_type] => utility [patent_app_number] => 12/948593 [patent_app_country] => US [patent_app_date] => 2010-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 10874 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12948593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9227503 [patent_doc_number] => 08633171 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-21 [patent_title] => 'Transparent oil gelling system' [patent_app_type] => utility [patent_app_number] => 12/890108 [patent_app_country] => US [patent_app_date] => 2010-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8365 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12890108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6163259 [patent_doc_number] => 20110160223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-30 [patent_title] => 'NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders' [patent_app_type] => utility [patent_app_number] => 12/938138 [patent_app_country] => US [patent_app_date] => 2010-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 38510 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0160/20110160223.pdf [firstpage_image] =>[orig_patent_app_number] => 12938138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8371276 [patent_doc_number] => 20120220665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'Inhibiting Neurotransmitter Reuptake' [patent_app_type] => utility [patent_app_number] => 13/505899 [patent_app_country] => US [patent_app_date] => 2010-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 15552 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13505899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9099737 [patent_doc_number] => 08563615 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-22 [patent_title] => 'Use of CI-994 and dinaline for the treatment of memory/cognition and anxiety disorders' [patent_app_type] => utility [patent_app_number] => 12/917402 [patent_app_country] => US [patent_app_date] => 2010-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 66 [patent_figures_cnt] => 92 [patent_no_of_words] => 23777 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12917402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6071264 [patent_doc_number] => 20110046115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-24 [patent_title] => 'Mirtazapine Solid Dosage Forms' [patent_app_type] => utility [patent_app_number] => 12/914478 [patent_app_country] => US [patent_app_date] => 2010-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8945 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0046/20110046115.pdf [firstpage_image] =>[orig_patent_app_number] => 12914478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8977481 [patent_doc_number] => 20130210911 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'METHOD AND COMPOSITION FOR TREATING A DISEASE OR CONDITION RELATED TO OREXIN RECEPTOR 1, OREXIN RECEPTOR 2, SOMATOSTATIN RECEPTOR 2 OR DOPAMINE D2L RECEPTOR' [patent_app_type] => utility [patent_app_number] => 13/509221 [patent_app_country] => US [patent_app_date] => 2010-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4750 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13509221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8371271 [patent_doc_number] => 20120220658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'Method for Treating Sepsis or Septic Shock' [patent_app_type] => utility [patent_app_number] => 13/503494 [patent_app_country] => US [patent_app_date] => 2010-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3233 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503494 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8417665 [patent_doc_number] => 20120245166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH' [patent_app_type] => utility [patent_app_number] => 13/501934 [patent_app_country] => US [patent_app_date] => 2010-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 11272 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13501934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9677020 [patent_doc_number] => 08815929 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-26 [patent_title] => 'Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists' [patent_app_type] => utility [patent_app_number] => 12/901755 [patent_app_country] => US [patent_app_date] => 2010-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5188 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12901755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6195447 [patent_doc_number] => 20110027201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-03 [patent_title] => 'METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS' [patent_app_type] => utility [patent_app_number] => 12/901911 [patent_app_country] => US [patent_app_date] => 2010-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5130 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20110027201.pdf [firstpage_image] =>[orig_patent_app_number] => 12901911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6128038 [patent_doc_number] => 20110086877 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-04-14 [patent_title] => 'Small Molecule Inhibitors of Botulinum Neurotoxins' [patent_app_type] => utility [patent_app_number] => 12/896338 [patent_app_country] => US [patent_app_date] => 2010-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13245 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0086/20110086877.pdf [firstpage_image] =>[orig_patent_app_number] => 12896338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5929984 [patent_doc_number] => 20110039943 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-17 [patent_title] => 'METHODS FOR TREATING SKIN DISORDERS WITH TOPICAL NITROGEN MUSTARD COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 12/890183 [patent_app_country] => US [patent_app_date] => 2010-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 25596 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20110039943.pdf [firstpage_image] =>[orig_patent_app_number] => 12890183 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8477810 [patent_doc_number] => 20120277218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DOWN SYNDROME' [patent_app_type] => utility [patent_app_number] => 13/497341 [patent_app_country] => US [patent_app_date] => 2010-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 13023 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9440978 [patent_doc_number] => 08710089 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-04-29 [patent_title] => 'Triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors' [patent_app_type] => utility [patent_app_number] => 12/880774 [patent_app_country] => US [patent_app_date] => 2010-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 46 [patent_no_of_words] => 66231 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12880774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8278498 [patent_doc_number] => 20120172370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-05 [patent_title] => 'PREPARATION OF CRYSTALLINE FORMS OF DIHYDROPYRAZOLOPYRIMIDINONE' [patent_app_type] => utility [patent_app_number] => 13/496014 [patent_app_country] => US [patent_app_date] => 2010-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 3144 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13496014 [rel_patent_id] =>[rel_patent_doc_number] =>)